Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.

Abstract

The alpha emitters (225)Ac and (213)Bi are promising therapeutic radionuclides for application in targeted alpha therapy of cancer and infectious diseases. Both alpha emitters are available with high specific activity from established radionuclide generators. Their favourable chemical and physical properties have led to the conduction of a large number of preclinical studies and several clinical trials, demonstrating the feasibility, safety and therapeutic efficacy of targeted alpha therapy with (225)Ac and (213)Bi. This review describes methods for the production of (225)Ac and (213)Bi and gives an overview of (225)Ac/(213)Bi radionuclide generator systems. Selected preclinical studies are highlighted and the current clinical experience with (225)Ac and (213)Bi is summarized.

• Authors: Alfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis
• Journal: Current radiopharmaceuticals (Curr Radiopharm) Vol. 5 Issue 3 Pg. 221-7 (Jul 2012) ISSN: 1874-4729 [Electronic] United Arab Emirates
• PMID: 22642390 (Publication Type: Journal Article, Review)

Chemical References

• Radioisotopes
• Radiopharmaceuticals
• Actinium
• Bismuth

Topics

• Actinium (isolation & purification, therapeutic use)
• Aged
• Aged, 80 and over
• Alpha Particles (therapeutic use)
• Animals
• Bismuth (isolation & purification, therapeutic use)
• Clinical Trials as Topic
• Humans
• Mice
• Mice, Transgenic
• Middle Aged
• Neoplasms (radiotherapy)
• Radioisotopes (isolation & purification, therapeutic use)
• Radionuclide Generators
• Radiopharmaceuticals (chemical synthesis, therapeutic use)